Eli Lilly's Tirzepatide Sales Reach $24.8 Billion, Bright Outlook Ahead
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Sales Surge: Eli Lilly's tirzepatide generated $24.8 billion in revenue during the first nine months of 2025, surpassing Keytruda as the world's best-selling drug, indicating strong performance in the weight loss market, with projections nearing $62 billion in sales by 2030.
- Competitive Edge: Despite pressure from rivals like Novo Nordisk in the weight loss drug market, Eli Lilly has solidified its market leadership with exceptional clinical trial results, particularly with retatrutide achieving an impressive 28.7% mean weight loss in phase 3 studies.
- Market Outlook: Eli Lilly's price-to-earnings ratio stands at 33, significantly above the healthcare sector average of 18.2, yet its revenue and earnings growth rates justify this premium, highlighting strong growth potential in the coming years.
- R&D Investment: Eli Lilly is advancing the approval process for orforglipron, expected to receive results by the end of February, with this expedited review process further enhancing its competitive position in the weight loss drug market and ensuring its leadership in the industry.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1085.190
Low
800.00
Averages
1078
High
1300
Current: 1085.190
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
